Floaria Bicher/iStock via Getty Images Arcellx, Inc. (NASDAQ:ACLX) is a biotechnology company with innovative oncology CAR-T cell therapies. ACLX leverages proprietary platforms, including D-Domain, ddCAR, and ARC-SparX, to enhance the immune system's capabilities to detect and kill cancer cells. Currently, ACLX’s leading product candidate is anitocabtagene autoleucel [anito-cel], which shows promising results in patients with relapsed/refractory multiple myeloma [r/r MM]. These results seem to also hol ...